Drug selection in the management of acute low back pain and sciatica: consideration of pain characteristics and drug metabolism

To the Editor, We are pleased to read the article titled ‘Comparison of Diclofenac with Tramadol, Tizanidine or Placebo in the Treatment of Acute Low Back Pain and Sciatica: Multi-center Randomized Controlled Trial,’ [1] which represents a valuable contribution to the field of acute low back pain (LBP) and sciatica management. The study’s meticulous design and rigorous execution reflect the authors’ dedication to addressing this pressing clinical challenge. Our observations aim to spark constructive dialogue and highlight additional avenues for extending the study’s relevance and influence in both research and clinical settings. Firstly, the study initially categorized patients into two groups: ‘lower back pain’ and ‘sciatica/radiating pain,’ providing a foundation for investigating the drug responses of patients with different pain types. However, this classification is overly simplistic, failing to further delineate the specific characteristics or etiologies of the pain, such as acute nonspecific pain versus pain caused by identifiable structural lesions (e.g. disc herniation or inflammatory diseases). The study reports that 90.4% of patients had purely lower back pain, while 9.6% had radiating pain; however, it does not provide more in-depth etiological data or stratified analysis. This limitation may obscure the potential impact of different etiologies and pain characteristics on treatment responses. For instance, the literature does not explore whether patients with radiating pain exhibit more pronounced effects with tramadol or tizanidine, which could be an underexplored avenue for research. To address this, future studies could refine patient classification further by confirming the presence of structural lesions at baseline through imaging techniques (such as MRI or CT) or neurological assessments. Additionally, subgroup analyses based on pain characteristics [2, 3], such as comparing nonspecific lower back pain with structurally induced radiating pain, might reveal distinct drug response patterns within specific populations. By combining the changes in functional recovery (RMDQ scores) and pain scores (NRS) mentioned in the study, and analyzing the magnitude and rate of changes across different subgroups, more targeted treatment recommendations could be provided.